View Older Stories View More Recent Stories

Jun 4, 2021 07:30AM Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
May 6, 2021 07:30AM Intellia Therapeutics Announces First Quarter 2021 Financial Results
Apr 29, 2021 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates
Apr 27, 2021 04:35PM Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting
Apr 12, 2021 07:30AM Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors
Mar 30, 2021 07:32AM Intellia Therapeutics (NTLA) Reports Investigational CRISPR Treatment NTLA-2001 Granted EU Orphan Drug Designation for ATTR Amyloidosis
Mar 30, 2021 07:30AM Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
Mar 25, 2021 07:30AM Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
Mar 10, 2021 07:31AM Intellia Therapeutics (NTLA) Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium
Mar 10, 2021 07:30AM Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium
Feb 25, 2021 07:30AM Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results
Feb 18, 2021 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates
Jan 7, 2021 07:30AM Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021
Dec 12, 2020 09:00AM Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency
Dec 5, 2020 10:00AM Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting
Nov 11, 2020 07:34AM Intellia Therapeutics (NTLA) Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments
Nov 11, 2020 07:30AM Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments
Nov 9, 2020 07:30AM Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
Nov 9, 2020 07:30AM Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
Nov 5, 2020 07:30AM Intellia Therapeutics Announces Third Quarter 2020 Financial Results
Oct 29, 2020 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates
Oct 19, 2020 07:31AM Intellia Therapeutics (NTLA) Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis
Oct 19, 2020 07:30AM Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)
Oct 19, 2020 07:30AM Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)
Oct 7, 2020 04:20PM Intellia Therapeutics (NTLA) Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry
Oct 7, 2020 04:20PM Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology
Oct 5, 2020 07:33AM Intellia Therapeutics (NTLA) Announces John F. Crowley to Board
Oct 5, 2020 07:30AM Intellia Therapeutics Names John F. Crowley to Board of Directors
Sep 29, 2020 08:20AM Intellia Therapeutics (NTLA) Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment
Sep 29, 2020 08:20AM Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment
Sep 28, 2020 08:00AM Intellia Therapeutics to Present at Chardan’s Virtual 4th Annual Genetic Medicines Conference
Sep 2, 2020 08:00AM Intellia Therapeutics to Present at Baird’s 2020 Virtual Global Healthcare Conference
Aug 6, 2020 07:30AM Intellia Therapeutics Announces Second Quarter 2020 Financial Results
Aug 3, 2020 08:00AM Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Jul 30, 2020 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates
Jun 1, 2020 07:04AM Regeneron (REGN) and Intellia Therapeutics (NTLA) Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
Jun 1, 2020 07:00AM Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
May 12, 2020 06:00AM Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
May 7, 2020 07:30AM Intellia Therapeutics Announces First Quarter 2020 Financial Results
Apr 30, 2020 07:50AM Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer
Apr 30, 2020 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates
Apr 28, 2020 04:30PM Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
Mar 31, 2020 07:38AM Intellia Therapeutics (NTLA) Announces FDA Accepts IND for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration
Mar 31, 2020 07:30AM FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics
Feb 27, 2020 07:30AM Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results
Feb 20, 2020 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update
Feb 10, 2020 07:30AM Intellia Therapeutics (NTLA) Presents New Data From Its Engineered Cell Therapy and In Vivo Programs
Feb 10, 2020 07:30AM Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference
Jan 9, 2020 07:30AM Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones
Nov 26, 2019 08:00AM Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference
View More Recent Stories View Older Stories